Innovative strides in immunology have brought forth transformative methodologies, and advances in vaccine research and development now encompass a new era of precision-driven prophylactics. Leveraging mRNA platforms, viral vector systems, and recombinant technologies, scientists are addressing both emerging and re-emerging infectious diseases with unprecedented speed and efficacy. From tailoring antigen design to enhancing adjuvant formulations, research is increasingly focusing on improving immunogenicity and cross-protection. Regulatory strategies and collaborative frameworks have also evolved, expediting approval pathways without compromising safety. Notably, global initiatives are emphasizing equitable access, ensuring that breakthroughs in vaccine science are translated into real-world impact. The integration of artificial intelligence and big data analytics is further optimizing vaccine candidate screening and predictive immunology. Advances in vaccine research and development reflect not just scientific innovation but also a commitment to global health resilience, marking a pivotal shift from reactive responses to proactive prevention strategies in public health systems worldwide.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey